Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | COL1A1 | P02452 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 2/20 | 0.31 |
| ▸ | TSPO | P30536 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13512034 | 0.86 | CRHR1 (0.34) | SIRT2CRHR1MEN1KMT2AHSD17B10 | |
| SCHEMBL26574685 | 0.80 | HRH3 (0.31) | — | |
| SCHEMBL14561848 | 0.79 | CRHR1 (0.30) | CRHR1MEN1KMT2AHSD17B10NPC1 | |
| SCHEMBL12751334 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL26575199 | 0.70 | — | — | |
| SCHEMBL13987032 | 0.69 | CRHR1 (0.32) | CRHR1MEN1KMT2AHSD17B10 | |
| SCHEMBL10029429 | 0.69 | NPC1 (0.34) | SIRT2CRHR1MEN1KMT2AHSD17B10 | |
| SCHEMBL16206237 | 0.66 | POLB (0.34) | SIRT2CRHR1NR1I2 | |
| SCHEMBL4848657 | 0.65 | — | — | |
| SCHEMBL27430107 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713361-B2 | Hydrogenation catalyst compositions and their use for hydrogenation of nitrile rubber | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11673130-B2 | Catalyst system containing a metathesis catalyst and at least one phenolic compound and a process for metathesis of nitrile-butadiene rubber (NBR) using the catalyst system | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| WO-2020020630-A2 | HYDROGENATION OF NITRILE RUBBER | ARLANXEO DEUTSCHLAND GMBH (DE) | 2020-01-30 | — | — | WO | disclosed |
| EP-3148693-B1 | CYCLIC BENT ALLENE METAL COMPLEXES | GOVERNING COUNCIL UNIV TORONTO (CA) | 2019-07-17 | — | — | EP | disclosed |
| US-20180223005-A1 | CATALYST COMPOSITIONS AND THEIR USE FOR HYDROGENATION OF NITRILE RUBBER | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-10011664-B2 | Functionalized nitrile rubbers and the production thereof | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10000584-B2 | Hydrogenation of nitrile rubber | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9920086-B2 | Ruthenium-based complexes, their preparation and use as catalysts | ARLANXEO DE GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9828401-B2 | Ruthenium-based complex catalysts | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| US-7737233-B2 | Catalyst systems and their use for metathesis reactions | LANXESS DEUTSCHLAND GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20100093944-A1 | CATALYST SYSTEMS AND THEIR USE FOR METATHESIS REACTIONS | LANXESS DEUTSCHLAND GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100087600-A1 | Catalyst Systems and their use for Metathesis Reactions | LANXESS DEUTSCHLAND GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| US-20090076226-A1 | CATALYSTS FOR METATHESIS REACTIONS | LANXESS DEUTSCHLAND GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076227-A1 | PROCESS FOR THE METATHETIC DEGRADATION OF NITRILE RUBBER | LANXESS DEUTSCHLAND GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090069516-A1 | CATALYST SYSTEMS AND THEIR USE FOR METATHESIS REACTIONS | LANXESS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090054597-A1 | Metathesis of Nitrile Rubbers In the Presence of Transition Metal Complex Catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-26 | — | — | US | disclosed |
| US-7470750-B2 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20080064822-A1 | Process for degrading nitrile rubbers in the presence of catalysts having an increased activity | ARLANXEO DEUTSCHLAND GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| US-20070049700-A1 | Method for the degradation of nitrile rubber by metathesis in the presence of ruthenium- or osmium-based catalysts | LANXESS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076226-A1 | CATALYSTS FOR METATHESIS REACTIONS | MCM4, MNS1, TERT | SIRT2 1811/4885CRHR1 4148/4885MEN1 201/4885 |
| US-20170327436-A1 | 1,3-BUTADIENE SYNTHESIS | SQLE, FDFT1, ENO1 | SIRT2 1257/4885CRHR1 1880/4885MEN1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.